drugset / Trial / NCT01318330

Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD)

NCT01318330 ↗

Phase 1 Completed 10 enrolled HomeoTherapy Co., Ltd
NaSingle-groupOpen-label

Summary

Official Title: Five-Week, Multi-center, Phase I Clinical Trial to Evaluate Safety of Homeo-GH after Intra Venus Administration for the Treatment of Graft versus Host Disease Patients Sponsor: HomeoTherapy Co.,Ltd Study Design: Single Group, Open Label, 5 Week, Safety Study This study is designed to evaluate the safety of ex-vivo cultured adult human clonal mesenchymal stem cells (cMSC) derived from human bone marrow in subjects experiencing acute or chronic graft-versus-host disease (GVHD). Study Type: Interventional

Timeline

Start
2010-11
Primary completion
2011-12
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Homeo-GH Cell therapy 1e+06 cells/kg Intravenous